Brii Biosciences to sell its stake in Qpex Biopharma to Shionogi for $24m
Additionally, Brii Bio will acquire exclusive global rights for the development and commercialisation of the novel lipopeptide BRII-693…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
26 Jun 23
Additionally, Brii Bio will acquire exclusive global rights for the development and commercialisation of the novel lipopeptide BRII-693…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Jun 23
After achieving primary endpoint by demonstrating superiority and non-inferiority in HbA1C reduction from baseline at week 52, investigative…
23 Jun 23
Elevidys (delandistrogene moxeparvovec-rokl) is an adeno-associated virus (AAV)-based gene therapy indicated for the treatment of ambulatory paediatric patients,…
23 Jun 23
The partnership is intended to combine Prime Medicine’s Prime Editing platform with Cimeio Therapeutics’ Shielded Cell and Immunotherapy…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Jun 23
Through the continued partnership, individuals affected by rare blood cancers, including various types of leukaemia, lymphoma, and myeloma,…
23 Jun 23
Now the iLet Bionic Pancreas is cleared for three insulins
22 Jun 23
Blincyto is a bispecific T-cell engager (BiTE) immuno-oncology therapy that targets CD19 surface antigens on B cells, to…
22 Jun 23
The primary focus of the funding will be to advance TGW101, Tagworks' leading click-cleavable ADC (Antibody-Drug Conjugate) programme,…
22 Jun 23
Umoja will leverage Ozette’s proprietary immune cell population discovery and annotation platform for novel oncology insights in preclinical…
22 Jun 23
Transformation has resulted in Ellab tripling its revenues, EBITDA and number of employees, while experiencing approximately 20% annual…